Compare LTC Properties Inc (LTC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Regeneron Pharmaceuticals Inc — how do they compare? LTC Properties Inc trades at $42 (market cap $2.15B), while Regeneron Pharmaceuticals Inc trades at $672.4 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 32.8× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.44%). Which is the better fit depends on your goals.
| LTC | REGN | |
|---|---|---|
Market Cap | $2.15B | $70.47B |
Sector | Real Estate | Health |
52-Week High | $41.92 | $812.27 |
52-Week Low | $33.98 | $545.46 |
Enterprise Value | $2.99B | $64.42B |
Dividend Yield | 5.44% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $41.92, up 0.41% with a bullish technical outlook. The REIT shows strong fundamentals with 2025 revenue of $263M and net income of $118M, supported by a 67.3% gross margin. Recent acquisitions expand its SHOP portfolio, targeting demographic trends in senior housing. Analyst sentiment is mixed with 27% buy ratings amid recent earnings misses.
Outlook: Growth driven by strategic acquisitions and aging demographics, but execution risks and debt levels warrant caution. Near-term focus on Q2 2026 earnings (expected EPS $0.48) as a key catalyst. Dividend yield of ~5.4% provides income appeal.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
